Imperial College London
Portrait Picture

Dr James Kinross

Faculty of Medicine, Department of Surgery & Cancer

Reader in General Surgery
 
 
 
//

Contact

 

+44 (0)20 3312 1947j.kinross

 
 
//

Location

 

1029Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Koller:2021:10.1136/bmjopen-2020-047162,
author = {Koller, KR and Wilson, A and Normolle, DP and Nicholson, JK and Li, JV and Kinross, J and Lee, FR and Flanagan, CA and Merculieff, ZT and Iyer, P and Lammers, DL and Thomas, TK and O'Keefe, SJD},
doi = {10.1136/bmjopen-2020-047162},
journal = {BMJ Open},
pages = {1--9},
title = {Dietary fibre to reduce colon cancer risk in Alaska Native people: the Alaska FIRST randomised clinical trial protocol.},
url = {http://dx.doi.org/10.1136/bmjopen-2020-047162},
volume = {11},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - INTRODUCTION: Diet, shown to impact colorectal cancer (CRC) risk, is a modifiable environmental factor. Fibre foods fermented by gut microbiota produce metabolites that not only provide food for the colonic epithelium but also exert regulatory effects on colonic mucosal inflammation and proliferation. We describe methods used in a double-blinded, randomised, controlled trial with Alaska Native (AN) people to determine if dietary fibre supplementation can substantially reduce CRC risk among people with the highest reported CRC incidence worldwide. METHODS AND ANALYSES: Eligible patients undergoing routine screening colonoscopy consent to baseline assessments and specimen/data collection (blood, urine, stool, saliva, breath and colon mucosal biopsies) at the time of colonoscopy. Following an 8-week stabilisation period to re-establish normal gut microbiota post colonoscopy, study personnel randomise participants to either a high fibre supplement (resistant starch, n=30) or placebo (digestible starch, n=30) condition, repeating stool sample collection. During the 28-day supplement trial, each participant consumes their usual diet plus their supplement under direct observation. On day 29, participants undergo a flexible sigmoidoscopy to obtain mucosal biopsy samples to measure the effect of the supplement on inflammatory and proliferative biomarkers of cancer risk, with follow-up assessments and data/specimen collection similar to baseline. Secondary outcome measures include the impact of a high fibre supplement on the oral and colonic microbiome and biofluid metabolome. ETHICS AND DISSEMINATION: Approvals were obtained from the Alaska Area and University of Pittsburgh Institutional Review Boards and Alaska Native Tribal Health Consortium and Southcentral Foundation research review bodies. A data safety monitoring board, material transfer agreements and weekly study team meetings provide regular oversight throughout the study. Study findings will first be shared with AN
AU  - Koller,KR
AU  - Wilson,A
AU  - Normolle,DP
AU  - Nicholson,JK
AU  - Li,JV
AU  - Kinross,J
AU  - Lee,FR
AU  - Flanagan,CA
AU  - Merculieff,ZT
AU  - Iyer,P
AU  - Lammers,DL
AU  - Thomas,TK
AU  - O'Keefe,SJD
DO  - 10.1136/bmjopen-2020-047162
EP  - 9
PY  - 2021///
SN  - 2044-6055
SP  - 1
TI  - Dietary fibre to reduce colon cancer risk in Alaska Native people: the Alaska FIRST randomised clinical trial protocol.
T2  - BMJ Open
UR  - http://dx.doi.org/10.1136/bmjopen-2020-047162
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34452959
UR  - https://bmjopen.bmj.com/content/11/8/e047162
UR  - http://hdl.handle.net/10044/1/91501
VL  - 11
ER  -
Download